Is Zoloft affected by genetics?

Yes — the active ingredient is metabolized by a gene known to vary between individuals.

Relevant genes: CYP2B6, CYP2C19

Used for: Depression, anxiety disorders, PTSD, OCD, premenstrual dysphoric disorder

Considering GeneSight for Zoloft?

Gene2Rx covers this medication using the same CPIC and FDA guidelines GeneSight uses, costs $5-$49 instead of several hundred, and works with your existing 23andMe data.

See the comparison →

Zoloft (sertraline) is one of the most-prescribed SSRIs, and a significant portion of the population-level variation in how people respond to it comes down to CYP2C19. Sertraline is metabolized by several enzymes, but CYP2C19 is the dominant one. Rapid metabolizers clear sertraline faster than expected, which means plasma levels may not reach the therapeutic range at standard doses, and patients can wait 6 to 8 weeks for an effect that simply isn't going to happen on that dose. Poor metabolizers have the reverse problem: sertraline accumulates, side effects (nausea, sexual dysfunction, sweating) are more prominent, and patients often discontinue before the benefit phase ever materializes.

What's in Zoloft

sertraline affected by CYP2B6, CYP2C19

Affected by CYP2B6, CYP2C19 · CPIC · Strong evidence

Sertraline is cleared primarily by CYP2C19 with contributions from CYP2B6, CYP2D6, and CYP3A4. CPIC guidelines are most developed for the CYP2C19 relationship. For rapid and ultrarapid metabolizers, CPIC recommends considering an alternative drug not predominantly metabolized by CYP2C19, such as fluoxetine or paroxetine. For poor metabolizers, a 50 percent dose reduction is suggested as a starting point, with close monitoring for side effects and efficacy. Response to SSRIs is multifactorial and pharmacogenetics is only one input, but it's the most actionable input.

Read the full sertraline genetics guide →

Sertraline phenotype recommendations

Published guidance from CPIC on how sertraline should be dosed or substituted based on your CYP2C19, CYP2B6 phenotype.

Phenotype	What it means	Recommendation	Evidence
Ultrarapid Metabolizer CYP2C19	Your body processes this drug slightly faster than average, but no dose change is needed.	CPIC Initiate therapy with recommended starting dose.	Optional
Rapid Metabolizer CYP2C19	Your body processes this drug slightly faster than average, but no dose change is needed.	CPIC Initiate therapy with recommended starting dose.	Optional
Normal Metabolizer CYP2C19	You can use the normal recommended dose for this medication.	CPIC Initiate therapy with recommended starting dose.	Strong
Intermediate Metabolizer CYP2C19	Your body processes this drug more slowly, so doctors may adjust the dose more carefully.	CPIC Initiate therapy with recommended starting dose. Consider a slower titration schedule and lower maintenance dose than CYP2C19 normal metabolizers.	Moderate
Likely Intermediate Metabolizer CYP2C19	Your body processes this drug more slowly, so doctors may adjust the dose more carefully.	CPIC Initiate therapy with recommended starting dose. Consider a slower titration schedule and lower maintenance dose than CYP2C19 normal metabolizers.	Moderate
Poor Metabolizer CYP2C19	Your body processes this drug much more slowly, so you may need a lower dose to avoid side effects.	CPIC Consider a lower starting dose, slower titration schedule, and 50% reduction of standard maintenance dose as compared with CYP2C19 normal metabolizers or select a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2C19.	Moderate
Likely Poor Metabolizer CYP2C19	Your body processes this drug much more slowly, so you may need a lower dose to avoid side effects.	CPIC Consider a lower starting dose, slower titration schedule, and 50% reduction of standard maintenance dose as compared with CYP2C19 normal metabolizers or select a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2C19.	Moderate
Indeterminate CYP2C19	The impact of your genotype on response to this drug is unknown.	CPIC Initiate therapy with recommended starting dose.	—
Not available CYP2C19	The impact of your genotype on response to this drug is unknown.	CPIC Initiate therapy with recommended starting dose.	—
Ultrarapid Metabolizer CYP2B6	Your body processes this drug a bit faster, but no dose change is usually needed.	CPIC Initiate therapy with recommended starting dose.	Optional
Rapid Metabolizer CYP2B6	Your body processes this drug a bit faster, but no dose change is usually needed.	CPIC Initiate therapy with recommended starting dose.	Optional
Normal Metabolizer CYP2B6	You can use the normal recommended dose for this medication.	CPIC Initiate therapy with recommended starting dose.	Strong
Intermediate Metabolizer CYP2B6	Your body processes this drug more slowly, so your doctor may adjust the dose more carefully.	CPIC Initiate therapy with recommended starting dose. Consider a slower titration schedule and lower maintenance dose than CYP2B6 normal metabolizers.	Moderate
Poor Metabolizer CYP2B6	Your body processes this drug much more slowly, so you may need a lower dose to avoid side effects.	CPIC Consider a lower starting dose, slower titration schedule, and 25% reduction of standard maintenance dose as compared with CYP2B6 normal metabolizers or select a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2B6.	Moderate
Indeterminate CYP2B6	The impact of your genotype on response to this drug is unknown.	CPIC Initiate therapy with recommended starting dose.	—

Source: CPIC

The gene behind the guidance

CYP2C19 Cytochrome P450 2C19

CYP2C19 handles several SSRIs (citalopram, escitalopram, sertraline), proton pump inhibitors (omeprazole, esomeprazole), and the blood thinner clopidogrel. About 2 to 5 percent of people of European descent and 15 to 20 percent of people of East Asian descent are poor metabolizers. Another 30 percent carry a rapid-metabolizer variant.

Rapid metabolizers clear affected drugs before they reach therapeutic levels. Poor metabolizers accumulate the drug and feel stronger effects.

See all drugs affected by CYP2C19 →

Browse the full drug-class: SSRI antidepressants.

What this means for you

If you've tried Zoloft and it didn't work (or wasn't tolerable), your CYP2C19 phenotype is one of the best-established reasons why. This is one of the highest-yield uses of pharmacogenetic testing for mental health: CYP2C19 genotype affects sertraline, citalopram, escitalopram, and the dosing of omeprazole and other PPIs, so a single test has ongoing utility. Share results with your prescriber before the next medication trial; many psychiatrists now incorporate CYP2C19 results into their prescribing flow.

FAQ

How long does it typically take to know if sertraline is working?

Clinical guidelines generally suggest 4 to 6 weeks at a therapeutic dose before concluding that an SSRI has failed. But if you're a CYP2C19 rapid or ultrarapid metabolizer on a standard dose, those weeks can be spent at sub-therapeutic plasma levels without anyone realizing it. That's part of why pharmacogenetic testing is most valuable before starting a trial, not after the fact.

If Zoloft didn't work, will Lexapro or Celexa?

Possibly not, because escitalopram (Lexapro) and citalopram (Celexa) are also metabolized primarily by CYP2C19. A patient whose CYP2C19 phenotype failed sertraline will often have the same issue with those two. CPIC specifically calls out this class of SSRIs as a group affected by CYP2C19 variation. A switch to a non-CYP2C19 SSRI (fluoxetine, paroxetine) or to an SNRI (duloxetine, venlafaxine) may be a better choice.

Is sertraline also affected by CYP2D6?

CYP2D6 contributes to sertraline metabolism but is not the dominant clearance pathway. Current CPIC guidance for sertraline is built around CYP2C19. If you've had CYP2D6 testing for other reasons (ADHD stimulants, codeine), the result is still useful context, but CYP2C19 is the primary gene to discuss with your prescriber for sertraline specifically.

Related medications

Find out how your genetics affect Zoloft

This page describes the general pharmacogenetics. A Gene2Rx report analyzes your own DNA to tell you which metabolizer group you fall into, across every medication.

Get your report Look up another medication

Informational only — not medical advice. Pharmacogenetic guidance describes population-level patterns; your individual response depends on many factors. Never start, stop, or change a medication without talking to your prescribing clinician.